Pharmaceutical company Savara reported positive interim results from an ongoing phase 2 study of Aironite in patients with pulmonary hypertension (PH) from multiple different etiologies. The company said Aironite significantly improved multiple hemodynamic measures, with most pronounced improvements in patients with pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF). It also resulted in significant overall decreases in right atrial pressure, systolic and diastolic right ventricular pressure, systolic and diastolic pulmonary artery pressure, and pulmonary capillary wedge pressure. Aironite was generally well-tolerated and no significant safety concerns were identified, supporting the primary safety outcome of the study.
The results “demonstrate that Aironite can significantly improve cardiopulmonary hemodynamics in HFpEF as well as Group 3 PH patients, both clinical conditions which are inadequately treated by currently approved medicinal treatments,” said Taneli Jouhikainen, chief operating officer of Savara. “We believe the product will have exciting potential to be advanced towards phase 3 studies an